Hepatitis D Viremia Among Injection Drug Users in San Francisco

J Infect Dis. 2018 May 25;217(12):1902-1906. doi: 10.1093/infdis/jiy157.

Abstract

People who inject drugs (PWID) are commonly exposed to hepatitis B virus (HBV) and hepatitis D virus (HDV). We evaluated the prevalence of HDV viremia among hepatitis B surface antigen (HBsAg)-positive PWID (n = 73) using a new quantitative microarray antibody capture (Q-MAC) assay, HDV western blot, and HDV RNA. HDV Q-MAC performed well in this cohort: anti-HDV, 100% sensitivity and specificity; HDV viremia, 61.5% sensitivity and 100% specificity. Hepatitis D viremia was present in 35.6% of HBsAg-positive participants and was more common in those with resolved compared to chronic hepatitis C (5.1% vs 0.6%; adjusted odds ratio, 9.80; P < .0001).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Coinfection / epidemiology
  • Coinfection / immunology
  • Coinfection / virology
  • Cross-Sectional Studies
  • Drug Users
  • Female
  • Hepatitis B / epidemiology
  • Hepatitis B / immunology
  • Hepatitis B / virology
  • Hepatitis B Antibodies / immunology
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B virus / immunology
  • Hepatitis B virus / pathogenicity
  • Hepatitis D / epidemiology*
  • Hepatitis D / immunology
  • Hepatitis D / virology
  • Hepatitis Delta Virus / immunology
  • Hepatitis Delta Virus / pathogenicity
  • Humans
  • Male
  • Middle Aged
  • Prevalence
  • Risk Factors
  • San Francisco / epidemiology
  • Substance Abuse, Intravenous / immunology
  • Substance Abuse, Intravenous / virology*
  • Viremia / epidemiology*
  • Viremia / immunology

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens